-
公开(公告)号:US07998969B2
公开(公告)日:2011-08-16
申请号:US12001947
申请日:2007-12-13
IPC分类号: C07D401/14 , C07D403/12 , A61K31/502
CPC分类号: C07D401/14 , C07D403/12 , C07D403/14 , C07D471/10
摘要: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5a, R5b, R6a, R6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
摘要翻译: 本发明提供了可用于治疗HIV感染或预防HIV感染或治疗AIDS或ARC的化合物。 本发明的化合物是式Ⅰ化合物,其中R1,R2,R3,R4,R5a,R5b,R6a,R6b和X如本文所定义。 本发明还公开了用本文定义的化合物治疗HIV感染的方法和含有所述化合物的药物组合物。
-
公开(公告)号:US20110028502A1
公开(公告)日:2011-02-03
申请号:US12847129
申请日:2010-07-30
申请人: Christine E. Brotherton-Pleiss , Joan Marie Caroon , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker
发明人: Christine E. Brotherton-Pleiss , Joan Marie Caroon , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker
IPC分类号: A61K31/513 , C07D239/22 , C07D403/12 , C07D401/14 , A61P29/00 , A61P11/00 , A61P11/06
CPC分类号: C07D403/12 , C07D239/22 , C07D401/12
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中m,n,R 1,R 2,R 3,R 4,R 5,R a和R b如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
13.
公开(公告)号:US08871760B2
公开(公告)日:2014-10-28
申请号:US12882514
申请日:2010-09-15
申请人: Christine E. Brotherton-Pleiss , Ralph New Harris, III , Bradley E. Loe , Francisco Javier Lopez-Tapia , Pankaj D. Rege , David Bruce Repke , Russell Stephen Stabler , Keith Adrian Murray Walker
发明人: Christine E. Brotherton-Pleiss , Ralph New Harris, III , Bradley E. Loe , Francisco Javier Lopez-Tapia , Pankaj D. Rege , David Bruce Repke , Russell Stephen Stabler , Keith Adrian Murray Walker
IPC分类号: A61K31/5383 , C07D498/04 , C07D513/04 , C07D487/04 , C07D471/04 , C07D491/20
CPC分类号: C07D487/04 , C07D471/04 , C07D491/20 , C07D498/04 , C07D513/04
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, and R3 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中X,Y,R 1,R 2和R 3如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
公开(公告)号:US08435990B2
公开(公告)日:2013-05-07
申请号:US12847129
申请日:2010-07-30
申请人: Christine E. Brotherton-Pleiss , Joan Marie Caroon , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker
发明人: Christine E. Brotherton-Pleiss , Joan Marie Caroon , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker
IPC分类号: C07D239/22 , C07D403/12 , A61K31/513
CPC分类号: C07D403/12 , C07D239/22 , C07D401/12
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中m,n,R 1,R 2,R 3,R 4,R 5,R a和R b如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
公开(公告)号:US20120149718A1
公开(公告)日:2012-06-14
申请号:US13324250
申请日:2011-12-13
IPC分类号: A61K31/4965 , C07D263/58 , C07D241/28 , C07D498/04 , C07D413/12 , C07D263/48 , A61K31/423 , A61K31/437 , A61K31/421 , A61K31/4439 , A61P19/02 , A61P29/00 , A61P25/06 , A61P11/00 , A61P11/06 , A61P3/10 , C07D241/20
CPC分类号: C07D241/20 , C07D241/28 , C07D263/48 , C07D263/58 , C07D413/12 , C07D498/04
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中变量如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
公开(公告)号:US08163929B2
公开(公告)日:2012-04-24
申请号:US12637940
申请日:2009-12-15
申请人: Jacob Berger , Christine E. Brotherton-Pleiss , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker , Shu-Hai Zhao
发明人: Jacob Berger , Christine E. Brotherton-Pleiss , Francisco Javier Lopez-Tapia , Keith Adrian Murray Walker , Shu-Hai Zhao
IPC分类号: C07D213/62 , A61K31/44
CPC分类号: C07D401/12 , C07D211/90 , C07D413/12 , C07D417/12
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, R1, R2, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中m,n,p,q,R 1,R 2,R 3,R 4,R 5和R 6如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
公开(公告)号:US20100160388A1
公开(公告)日:2010-06-24
申请号:US12637903
申请日:2009-12-15
IPC分类号: A61K31/4412 , C07D213/78 , A61P19/02 , A61P37/06
CPC分类号: C07D211/86 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
摘要翻译: 式I化合物或其药学上可接受的盐,其中m,n,R 1,R 2,R 3,R 4和R 5如本文所定义。 还公开了制备化合物和使用该化合物治疗与P2X7嘌呤能受体有关的疾病的方法。
-
公开(公告)号:US07491821B2
公开(公告)日:2009-02-17
申请号:US11502797
申请日:2006-08-11
申请人: Christine E. Brotherton-Pleiss , Michael Patrick Dillon , Shelley K. Gleason , Clara Jeou Jen Lin , Ryan Craig Schoenfeld , Marzia Villa , Yansheng Zhai
发明人: Christine E. Brotherton-Pleiss , Michael Patrick Dillon , Shelley K. Gleason , Clara Jeou Jen Lin , Ryan Craig Schoenfeld , Marzia Villa , Yansheng Zhai
IPC分类号: C07D403/12 , C07D413/12 , C07D417/12 , C07D295/194
CPC分类号: C07D213/81 , C07D231/56 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要: Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genitourinary, gastrointestinal, and respiratory disorders: wherein R1 is —C(═S)CH3, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R2a and R2b are independently H, methyl, or ethyl; R3 is H or methyl; Y is a bond, —(CR4R5)n— or —CR4═CR5—; wherein R4 and R5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R6, R7 and R8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R6 and R7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.
-
-
-
-
-
-
-